Brain

Dräger Evita V800/V600, Babylog VN800 and Savina 300 obtain Authority to Operate (ATO) under Risk Management Framework

New certifications follow Dräger's previous ATO certification for a critical care ventilator Dräger Evita V800/V600 and Babylog VN800 family of…

10 months ago

Stellaromics Secures Significant Funding to Advance 3D Spatial Biology

Investment Powers the Debut of Pyxa: A Groundbreaking Platform for 3D Spatial Biology Research BOSTON, Feb. 11, 2025 /PRNewswire/ -- Stellaromics,…

10 months ago

Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment

Collaboration Aims to Develop First Intranasal Therapy for Mild Traumatic Brain Injury Aka Concussion, Establishing a Comprehensive Test-to-Treat PlatformSARASOTA, Fla.…

10 months ago

Achieve Life Sciences to Present at the Oppenheimer Healthcare Life Sciences Conference

SEATTLE and VANCOUVER, British Columbia, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical…

10 months ago

Firefly Neuroscience Accepted into NVIDIA Connect Program

Collaboration to provide Firefly with the technical resources to help further unleash the power of its FDA-cleared BNA™ platform          For…

10 months ago

Digital Safety Alliance Marks One-Year Anniversary with the Launch of Digital Safety Virtual Assistant

MIAMI, Feb. 10, 2025 /PRNewswire/ -- The Digital Safety Alliance (DSA) is proud to celebrate its one-year anniversary with the…

10 months ago

Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition

HOUSTON, TEXAS, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader…

10 months ago

Achieve Life Sciences Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial

No Safety Concerns Identified by DSMC in the ORCA-OL Long-Term Exposure Trial Achieve Reiterates Planned Cytisinicline NDA Submission in Q2…

10 months ago

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

February 10, 2025 Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis Underscores unmet need for…

10 months ago

Grace Therapeutics Announces Private Placement Financing of up to $30 Million

Financing led by Nantahala Capital and ADAR1 Partners, LP with participation from new and existing healthcare-focused institutional investors $15 million…

10 months ago